Ioxilan is a diagnostic contrast agent.[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017.[2]

Mechanism of action

Ioxilan is an iodinated contrast agent.[2]

References

  1. ^ Cheng KT (December 2007). "Ioxilan carbonate particles". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641969.
  2. ^ a b Oxilan FDA Professional Drug Information. Accessed 2021-04-07.
Allikas: https://en.wikipedia.org/wiki/Ioxilan
No tags for this post.